Teladoc Health 在2025年第四季度的盈利预期中表现优于预期，但在持续的增长和盈利挑战下发布了较弱的2026年指引。 Teladoc Health beat earnings estimates in Q4 2025 but issued weak 2026 guidance amid ongoing growth and profitability challenges.

Teladoc Health报告,经调整的2025年第4季度EPS为 - 14美元,粗略估计,收入为6.423亿美元,年同比不变。 Teladoc Health reported Q4 2025 adjusted EPS of -$0.14, beating estimates, with revenue of $642.3 million, flat year-over-year. 公司减少了净亏损,但发布了低于分析师预期的弱势第一季度和2026年全年预测. The company narrowed its net loss but issued weak Q1 and full-year 2026 guidance below analyst expectations. 尽管美国综合护理成员逐年增长8.5%,但每个用户的平均收入下降了7.6%,前瞻性指导反映了在收入增长和盈利方面持续存在的挑战。 Despite 8.5% year-over-year growth in U.S. integrated care members, average revenue per user dropped 7.6%, and forward guidance reflects ongoing challenges in revenue growth and profitability. 股票交易额大约为4.66美元。 The stock traded around $4.66.